Anavex Life Sciences (AVXL) Proxy filing summary

Executive summary

• Focus on advancing blarcamesine (ANAVEX®2-73) for Alzheimer's, Rett syndrome, and Fragile X syndrome, with regulatory engagement prioritized for these indications.

• Interim leadership and governance changes implemented following the termination of the former CEO for cause; Board stability and capital efficiency are emphasized.

• Company maintains a strong cash position with no long-term debt and is committed to maximizing shareholder value.

Voting matters and shareholder proposals

• Stockholders will vote to elect six directors and to ratify Grant Thornton LLP as the independent auditor for fiscal 2026.

• A contested election is underway, with the PVG Group nominating an opposing slate of six directors; the Board recommends voting only for its nominees.

• Universal proxy card includes both company and PVG Group nominees; shareholders are urged to vote for only six Board-recommended nominees.

Board of directors and corporate governance

• Board consists of six members, all determined to be independent under Nasdaq rules.

• Executive Committee established to manage company affairs during leadership transition; Dr. Jiong Ma serves as independent Board Chair.

• Board committees (Audit, Compensation, Nominating/Governance) operate under formal charters and met regularly in fiscal 2025.

• Board diversity is considered, though no formal diversity policy exists.